《新股表现》荣昌(09995.HK)高开16%报60.6元
荣昌生物制药(09995.HK)暗盘收59.9元,高上市价15%;该股首挂开报60.6元,较上市价52.1元,高逾16%,市前成交1,162万股。
荣昌是内地一家正在进入商业化阶段的生物制药公司,其致力於发现、开发和商业化创新的、有特色的生物药,用於治疗中国乃至全球多种医疗需求未被满足自身免疫、肿瘤科和眼科疾病。是次来港上市共发售7,653.7万股H股,并已引入包括富达基金、贝莱德、GIC及中生制药(01177.HK)等19名基石投资者,合共认购3,383.95万股;10%公开发售获52.4倍超购,已启动回拨机制占比增至40%,认购一手中签率90%;股份以招股范围(50.3-52.1元)上限定价,料集资净额约37.77亿元,主要用作候选药物临床开发和商业化、拨付建设新生产设施及还债等。上市联席保荐人分别为大摩、摩通及华泰金控香港。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.